/PRNewswire/ Piramal Pharma Limited (NSE: PPLPHARMA) (BSE: 543635), today announced its consolidated results for the fourth quarter (Q4) and full year FY23.
MUMBAI, India, May 24, 2023 /PRNewswire/ Piramal Pharma Limited (NSE: PPLPHARMA) (BSE: 543635), today announced its consolidated results for the fourth quarter (Q4) and full year FY23 ended
/PRNewswire/ Piramal Pharma Limited (NSE: PPLPHARMA) (BSE: 543635), today announced its consolidated results for the fourth quarter (Q4) and full year FY23.
TheracosBio recently received FDA approval for Brenzavvy (bexagliflozin), an oral sodium-glucose cotransporter 2 (SGLT2) inhibitorPiramal supported TheracosBio with starting materials, active